A Large Multi-centre European Study Validates High-sensitivity C-reactive Protein (hsCRP) As a Clinical Biomarker for the Diagnosis of Diabetes Subtypes

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2011 Aug 5

PMID 21814873

Citations 51

Authors

G Thanabalasingham

N Shah

M Vaxillaire

T Hansen

T Tuomi

D Gasperikova

M Szopa

E Tjora

T J James

P Kokko

F Loiseleur

E Andersson

S Gaget

B Isomaa

N Nowak

H Raeder

J Stanik

P R Njolstad

M T Malecki

I Klimes

L Groop

O Pedersen

P Froguel

M I McCarthy

A L Gloyn

K R Owen

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: An accurate molecular diagnosis of diabetes subtype confers clinical benefits; however, many individuals with monogenic diabetes remain undiagnosed. Biomarkers could help to prioritise patients for genetic investigation. We recently demonstrated that high-sensitivity C-reactive protein (hsCRP) levels are lower in UK patients with hepatocyte nuclear factor 1 alpha (HNF1A)-MODY than in other diabetes subtypes. In this large multi-centre study we aimed to assess the clinical validity of hsCRP as a diagnostic biomarker, examine the genotype-phenotype relationship and compare different hsCRP assays.

Methods: High-sensitivity CRP levels were analysed in individuals with HNF1A-MODY (n = 457), glucokinase (GCK)-MODY (n = 404), hepatocyte nuclear factor 4 alpha (HNF4A)-MODY (n = 54) and type 2 diabetes (n = 582) from seven European centres. Three common assays for hsCRP analysis were evaluated. We excluded 121 participants (8.1%) with hsCRP values >10 mg/l. The discriminative power of hsCRP with respect to diabetes aetiology was assessed by receiver operating characteristic curve-derived C-statistic.

Results: In all centres and irrespective of the assay method, meta-analysis confirmed significantly lower hsCRP levels in those with HNF1A-MODY than in those with other aetiologies (z score -21.8, p < 5 × 10(-105)). HNF1A-MODY cases with missense mutations had lower hsCRP levels than those with truncating mutations (0.03 vs 0.08 mg/l, p < 5 × 10(-5)). High-sensitivity CRP values between assays were strongly correlated (r (2) ≥ 0.91, p ≤ 1 × 10(-5)). Across the seven centres, the C-statistic for distinguishing HNF1A-MODY from young adult-onset type 2 diabetes ranged from 0.79 to 0.97, indicating high discriminative accuracy.

Conclusions/interpretation: In the largest study to date, we have established that hsCRP is a clinically valid biomarker for HNF1A-MODY in European populations. Given the modest costs and wide availability, hsCRP could translate rapidly into clinical practice, considerably improving diagnosis rates in monogenic diabetes.

Citing Articles

Longitudinal evaluation of manufacturer-specific differences for high-sensitive CRP EQA results.

Weiss N, Vierbaum L, Kremser M, Kaufmann-Stoeck A, Kappler S, Ballert S Front Mol Biosci. 2024; 11:1401405.

PMID: 39176390 PMC: 11338768. DOI: 10.3389/fmolb.2024.1401405.

The use of precision diagnostics for monogenic diabetes: a systematic review and expert opinion.

Murphy R, Colclough K, Pollin T, Ikle J, Svalastoga P, Maloney K Commun Med (Lond). 2023; 3(1):136.

PMID: 37794142 PMC: 10550998. DOI: 10.1038/s43856-023-00369-8.

De novo HNF1A mutation of young maturity-onset diabetes 3 of a young girl-Case report.

Peng H, Li J, Wang Z BMC Endocr Disord. 2023; 23(1):38.

PMID: 36782183 PMC: 9926701. DOI: 10.1186/s12902-023-01293-7.

Variants influencing age at diagnosis of HNF1A-MODY.

Ludwig-Slomczynska A, Seweryn M, Radkowski P, Kapusta P, Machlowska J, Pruhova S Mol Med. 2022; 28(1):113.

PMID: 36104811 PMC: 9476297. DOI: 10.1186/s10020-022-00542-0.

Maturity Onset Diabetes of the Young-New Approaches for Disease Modelling.

Skoczek D, Dulak J, Kachamakova-Trojanowska N Int J Mol Sci. 2021; 22(14).

PMID: 34299172 PMC: 8303136. DOI: 10.3390/ijms22147553.

References

Pearson E, Boj S, Steele A, Barrett T, Stals K, Shield J . Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007; 4(4):e118. PMC: 1845156. DOI: 10.1371/journal.pmed.0040118. View

Pearson E, Starkey B, Powell R, Gribble F, Clark P, Hattersley A . Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003; 362(9392):1275-81. DOI: 10.1016/S0140-6736(03)14571-0. View

Ford E, Giles W, Myers G, Rifai N, Ridker P, Mannino D . C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem. 2003; 49(8):1353-7. DOI: 10.1373/49.8.1353. View

Lee C, Adler A, Sandhu M, Sharp S, Forouhi N, Erqou S . Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009; 52(6):1040-7. DOI: 10.1007/s00125-009-1338-3. View

Bellanne-Chantelot C, Carette C, Riveline J, Valero R, Gautier J, Larger E . The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes. 2007; 57(2):503-8. DOI: 10.2337/db07-0859. View

Reiner A, Barber M, Guan Y, Ridker P, Lange L, Chasman D . Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet. 2008; 82(5):1193-201. PMC: 2427318. DOI: 10.1016/j.ajhg.2008.03.017. View

Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njolstad P, Hansen T . The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2002; 45(3):427-35. DOI: 10.1007/s00125-001-0770-9. View

Ridker P, Pare G, Parker A, Zee R, Danik J, Buring J . Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet. 2008; 82(5):1185-92. PMC: 2427311. DOI: 10.1016/j.ajhg.2008.03.015. View

MOSES L, Shapiro D, Littenberg B . Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993; 12(14):1293-316. DOI: 10.1002/sim.4780121403. View

10.

Shih D, Bussen M, Sehayek E, Ananthanarayanan M, Shneider B, Suchy F . Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet. 2001; 27(4):375-82. DOI: 10.1038/86871. View

11.

Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G . Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J. 1990; 9(13):4467-75. PMC: 552239. DOI: 10.1002/j.1460-2075.1990.tb07897.x. View

12.

Alberti K, Zimmet P, Shaw J . Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006; 23(5):469-80. DOI: 10.1111/j.1464-5491.2006.01858.x. View

13.

Pal A, Farmer A, Dudley C, Selwood M, Barrow B, Klyne R . Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care. 2009; 33(2):252-7. PMC: 2809258. DOI: 10.2337/dc09-1246. View

14.

Passing H, Bablok . A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem. 1983; 21(11):709-20. DOI: 10.1515/cclm.1983.21.11.709. View

15.

Whincup P, Nightingale C, Owen C, Rudnicka A, Gibb I, McKay C . Early emergence of ethnic differences in type 2 diabetes precursors in the UK: the Child Heart and Health Study in England (CHASE Study). PLoS Med. 2010; 7(4):e1000263. PMC: 2857652. DOI: 10.1371/journal.pmed.1000263. View

16.

Ridker P . Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107(3):363-9. DOI: 10.1161/01.cir.0000053730.47739.3c. View

17.

Freeman D, Norrie J, Caslake M, Gaw A, Ford I, Lowe G . C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002; 51(5):1596-600. DOI: 10.2337/diabetes.51.5.1596. View

18.

McCarthy M . Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010; 363(24):2339-50. DOI: 10.1056/NEJMra0906948. View

19.

Murphy R, Ellard S, Hattersley A . Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab. 2008; 4(4):200-13. DOI: 10.1038/ncpendmet0778. View

20.

Owen K, Thanabalasingham G, James T, Karpe F, Farmer A, McCarthy M . Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care. 2010; 33(9):1919-24. PMC: 2928334. DOI: 10.2337/dc10-0288. View